Fight Colorectal Cancer

Having trouble reading this email? View it on our website.

May 2011

Tell Us About Yourself
We want to make sure the Fight Colorectal Cancer e-news is interesting to YOU. Please take a quick minute to answer a very short survey. Your answers will remain absolutely confidential and will help us determine what kind of news our readers really want to see. Thank you!

Click here for survey.

Are you Newly Diagnosed?
hands Check out Fight Colorectal Cancer's centralized web page for those just getting used to their new reality of living with colorectal cancer.

There is a lot of information to take in, so we've narrowed the focus into a few main sections: Overview, treatments, clinical trials, and other resources.

Encouraging News for Metastatic Patients
trialTwo pharmaceutical companies have announced positive results for a trial testing a potential treatment for metastatic colorectal cancer.

The drug, called ZALTRAP® (aflibercept), added to survival time when given along with FOLFIRI to colorectal cancer patients who had already progressed on earlier Eloxatin (oxaliplatin) treatment. Aflibercept, also called "VEGF trap," is a specially developed protein that can block the development of new blood vessels as it circulates in the blood stream or in the spaces between blood vessels near tumors. It acts on two different vascular endothelial growth factors (VEGF) as well as placental growth factor (PIGF). We'll update details as they are reported at an upcoming medical conference.

Read more.

Disclosure: Fight Colorectal Cancer has accepted funding for projects and educational programs from sanofi-aventis in the form of unrestricted educational grants. Fight Colorectal Cancer has ultimate authority over e-newsletter content.

Stamping Out Colorectal Cancer
StampLegislation pending in Congress will create a colorectal cancer postage stamp that would help raise money for research. The Fight Colorectal Cancer Stamp Act, HR 893, will help increase funding for colorectal cancer even during difficult economic times without raising taxes. A similar stamp for breast cancer has raised over $70 million for research.

But we need your help. In order for this to become a reality, it must first pass in the US House and Senate.

Please contact your Representative about this legislation today.

Updates from Digestive Disease Week 2011
The largest gathering of physicians and researchers in gastroenterology and other digestive fields met last week in Chicago as part of Digestive Disease Week. Fight Colorectal Cancer was there and has this to report:

  • Knowing if a young patient's tumor has microsatellite instability (also referred to as "MSI-High") before surgery helps doctors and patients make better surgical plans, according to a Mayo Clinic study. Microsatellite screening identifies patients who might have Lynch syndrome and would benefit from having a complete colectomy along with a hysterectomy if they are female.
  • Although men have more colon polyps than women, both sexes have similar rates of colorectal cancer. Dr. Joseph Anderson at the University of Connecticut wanted to know why, so he used a high-definition colonoscope to see if women's adenomas were different from men's. He found that women have almost four times as many advanced flat adenomas in the upper part of the colon where they are hardest to detect and most likely to be missed during screening.

Clinical Trial Spotlight - Peritoneal carcinomatosis
volunteer for trialA clinical trial at the National Institutes of Health Clinical Center in Bethesda will explore whether a second surgery to look for peritoneal carcinomatosis (PC) in high-risk patients can find the disease earlier, treat it appropriately and improve survival.

Eligible patients for the trial will have already had surgery that removed all visible tumor and are considered to have no evidence of disease (NED). However, their cancer will have some high-risk features that make it more likely that they might develop PC in the future.

A year after their original colon or rectal surgery, they will be randomly assigned to (1) standard-of-care follow-up testing with blood tests and CT scans or a (2) mandatory second-look surgery. If the second look finds PC, they'll be treated immediately with surgery to remove all visible tumor and heated intraperitoneal chemotherapy (HIPEC).

Find out more about the trial.


Upcoming Patient Webinars

Understanding & Navigating Cancer Clinical Trials
June 1, 2011
8-9:30 PM Eastern

The Big News in CRC from the 2011 ASCO Meeting
June 20, 2011
8-9 PM Eastern

View Past Webinars

Treating Liver Mets
If you missed Monday's webinar on treatments for liver metastases, you can view it online along with other patient webinars that have taken place.
Watch Now

My Colon Cancer Coach


Fight Colorectal Cancer and Genomic Health Inc. have launched My Colon Cancer Coach, a unique, online tool for newly diagnosed colon cancer patients that provides a free, personalized treatment report. The questionnaire takes less than 10 minutes to complete and empowers patients to discuss treatment options with their physician.

Clinical Trial Matching Service


Shop With a Purpose

We Care Logo

Fight Colorectal Cancer has a trusted partnership with We-Care.com. By visiting our We-Care.com online mall, you can shop over 1,500 stores and a percentage of what you spend will be returned to Fight Colorectal Cancer – at no extra cost to you. So get shopping!

Answer Line takes your calls
Get answers to your questions about your disease, treatment options and available clinical trials. Answer Line Associates are ready to take your call Monday - Friday, 9 AM - 5 PM Eastern. Ask your question online.

Fight Colorectal Cancer demands a cure for colon and rectal cancer. We educate and support patients and caregivers, push for changes in policy that will increase and improve research, and empower survivors to raise their voices against the status quo.
Telephone: 703 548 1225 | Toll-Free Answer Line: 1 877 427 2111 • Please Donate
Email: Info@FightColorectalCancer.org

You received this message because  has opted in to receive email from Colorectal Cancer Coalition.
Would you like to unsubscribe or change your email preferences?